I completed dermatology residency in 2002, the primary treatment options for severe plaque psoriasis consisted of methotrexate, acitretin, and cyclosporine. Fast-forward 19 years and we find ourselves in an "arms race" as increasingly efficacious biologic therapies continually raise the bar of acceptable disease response. For instance, a pair of recent phase 3 psoriasis trials in the New England Journal of Medicine used primary outcomes of Psoriasis Area and Severity Index (PASI) 90 1 and PASI 100 2 to compare bimekizumab, a monoclonal immunoglobulin G1 inhibitor of interleukin (IL)-17A and IL-17F, with adalimumab and secukinumab, respectively. After 16 weeks of bimekizumab treatment, PASI 90 was achieved in 86.2% of patients in the first trial, 1 and PASI 100 was achieved in 61.7% of patients in the second trial. 2 In tandem with extraordinary responses such as these, the dosing frequency of injected biologic agents has evolved from twice per week (etanercept) to as infrequently as once every 12 weeks (tildrakizumab, risankizumab). Other oral agents (apremilast, tofacitinib) are now available that are safe and effective for patients with psoriasis and/or psoriatic arthritis.Lost amid this success story, however, is the reality that nearly all psoriasis trials exclude pustular psoriasis and its variants. Hundreds of millions of dollars have been devoted to the development of blockbuster drugs that are highly effective for psoriasis vulgaris, but there remains no US Food and Drug Administration-approved treatment for either localized or generalized pustular psoriasis (GPP). American Academy of Dermatology-National Psoriasis Foundation consensus recommendations for off-label pustular disease management are based on expert opinion, case reports, or case series, with a few exceptions. [3][4][5][6] Nevertheless, we have learned much about the biology of pustular psoriasis during the past decade from the study of monogenic diseases. In 2009, Aksentijevich and colleagues 7 at the National Institutes of Health described a severe, neonatalonset form of pustular psoriasis with systemic inflammation termed deficiency of the IL-1 receptor antagonist, or DIRA (OMIM 612852). These children respond quickly and dramatically to treatment with recombinant IL-1 receptor antagonist therapy. Two years later, Marrakchi et al 8 reported an analogous form of variable-age-onset pustular psoriasis (known as DITRA) caused by deficiency of the IL-36 receptor antagonist, IL-36Ra, which is encoded by the IL36RN gene (OMIM 614204). Subsequent sequencing studies have demonstrated that variants in IL36RN may be responsible for 19% to 41% of GPP and have also linked pathogenic variants in CARD14, AP1S3, SERPINA3, and myeloperoxidase with GPP. 9 These discover-Related articles pages 73 and 68 Opinion EDITORIAL jamadermatology.com (Reprinted)